Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. Dezember 2020 08:00 ET | Quelle: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Announces Leadership Transition

Jerry Durso Appointed CEO Effective January 1, 2021;Founder, President and CEO Mark Pruzanski to Continue as Board Member and Advisor NEW YORK, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Intercept...
24. November 2020 07:00 ET | Quelle: Intercept Pharmaceuticals, Inc.

Intercept to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
16. November 2020 08:00 ET | Quelle: Intercept Pharmaceuticals, Inc.

New Data from the Interim Analysis of REGENERATE Show OCA Improved Noninvasive Measures of Fibrosis in a Subgroup of High-Risk Patients with Fibrosis Due to NASH

NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
09. November 2020 07:00 ET | Quelle: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Reports Third Quarter 2020 Financial Results, Announces Updates to Financial Guidance and Provides Business Update

Worldwide Ocaliva net sales of $79.5 million in the third quarter 2020, representing 29% growth over the prior year quarter Intercept updates 2020 Ocaliva Net Sales Guidance to narrow the range to...
02. November 2020 16:00 ET | Quelle: Intercept Pharmaceuticals, Inc.

Intercept to Announce Third Quarter 2020 Financial Results on November 9, 2020

NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
29. Oktober 2020 08:00 ET | Quelle: Intercept Pharmaceuticals, Inc.

New PBC and NASH Data to be Presented at AASLD’s The Liver Meeting Digital Experience™

Presentation of long-term efficacy and safety data of obeticholic acid (OCA) for the treatment of patients with PBC Analysis from Phase 3 REGENERATE study examines the antifibrotic efficacy of OCA on...
03. September 2020 08:00 ET | Quelle: Intercept Pharmaceuticals, Inc.

Intercept to Present at September Investor Conference

NEW YORK, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
27. August 2020 08:00 ET | Quelle: Intercept Pharmaceuticals, Inc.

New Data from the Interim Analysis of REGENERATE Show that OCA Helped Patients with Liver Fibrosis Due to NASH Achieve Sustained Improvement in Noninvasive Markers of Fibrosis Over Two Years of Treatment

NEW YORK, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
21. August 2020 08:00 ET | Quelle: Intercept Pharmaceuticals, Inc.

Intercept to Present New NASH and PBC Data at the Digital International Liver Congress™ 2020

New analyses of the interim analysis data from the Phase 3 REGENERATE study describe the benefit of obeticholic acid (OCA) on noninvasive measures of liver fibrosis in NASH patients on treatment for...
10. August 2020 07:00 ET | Quelle: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Reports Second Quarter 2020 Financial Results, Announces Updates to Financial Guidance and Provides Business Update

Worldwide Ocaliva net sales of $77.2 million in the second quarter 2020, representing 17% growth over the prior year quarter Intercept issues 2020 Ocaliva Net Sales Guidance of $300 to $320 million ...

Vorherige Seite

Nächste Seite